In patients with type 2 diabetes, chronic kidney disease, and risk of cardiovascular disease, the contraindication is to use a sodium–glucose transport inhibitor; only 61 physicians (26.1%) use finerenone, which is recommended to prevent and delay progression in kidney disease if an SGLT2 inhibitor is contraindicated. This evidence concerns the gene SLC5A2 and kidney disorder.